BioSpace News Archive

Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, will be at the American Academy of Orthopedic Surgeons (AAOS) 2021 Annual Meeting, September 1-3, 2021, in San Diego.

AtriCure to Participate at the Morgan Stanley 19 th Annual Global Healthcare Conference

Tenaya Therapeutics to Present at Morgan Stanley 19 th Annual Global Healthcare Conference

Hyperfine Inc. , creator of the first FDA-cleared portable magnetic resonance imaging (MRI) device, Swoop™, has appointed Kyla Pavlina, J.D., as chief people officer.

Amylyx Pharmaceuticals, Inc. today announced that Health Canada has accepted for review the New Drug Submission (NDS) for AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS).

Longboard Pharmaceuticals, Inc. today announced that Kevin R. Lind, Longboard’s President & Chief Executive Officer, will present virtually in a fireside chat format at two upcoming investor conferences: Citi’s 16th Annual BioPharma Virtual Conference and H.C. Wainwright’s 23rd Annual Global Investment Conference.

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), announces it has successfully enrolled 302 patients across 25 clinical sites and has now closed enrollment for its ONWARD™ Phase 3 trial.

Vitro Biopharma, Inc. announced the acquisition of Fitore Nutrition and Infinivive MD. Fitore, a private company headquartered in Denver, Colorado creates clinically validated supplements and sells them direct to consumers via their unique digital marketing platform and SEO expertise.

To drive awareness of interstitial lung disease (ILD), nine organizations are collaborating to present the first-ever ILD Day on Wednesday, Sept. 15 . There are more than 200 types of ILD, which is the umbrella term used for a large group of diseases characterized by inflammation and/or scarring in the lungs.

Poseida Therapeutics, Inc. today announced preliminary results from its Phase 1 clinical trial of P-PSMA-101, the Company’s solid tumor autologous CAR-T product candidate to treat patients with metastatic castrate-resistant prostate cancer (mCRPC).